This overview may include historically adjusted values in order to ensure comparability with 2011.
| XLS |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
€ million |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
Change | ||||||||
| |||||||||||||||||||
|
Total revenues by division |
7,521 |
7,364 |
6,017 |
5,887 |
6,310 |
7,081 |
7,590 |
7,747 |
9,291 |
10,276 |
11 | ||||||||
|
Pharmaceuticals |
3,265 |
3,458 |
3,601 |
3,905 |
4,163 |
4,900 |
5,456 |
5,812 |
6,226 |
6,416 |
3.1 | ||||||||
|
Merck Serono |
1,850 |
1,546 |
1,619 |
1,817 |
1,938 |
4,480 |
5,014 |
5,345 |
5,754 |
5,920 |
2.9 | ||||||||
|
Generics1 |
1,096 |
1,585 |
1,625 |
1,712 |
1,825 |
– |
– |
– |
– |
– |
– | ||||||||
|
Consumer Health Care |
319 |
327 |
357 |
376 |
400 |
420 |
442 |
467 |
472 |
496 |
5.1 | ||||||||
|
Chemicals |
1,791 |
1,707 |
1,696 |
1,906 |
2,113 |
2,152 |
2,127 |
1,935 |
3,065 |
3,860 |
26 | ||||||||
|
Merck Millipore |
– |
– |
– |
– |
– |
– |
– |
– |
1,6134 |
2,393 |
48 | ||||||||
|
Performance Materials |
– |
– |
– |
– |
– |
– |
– |
– |
1,4524 |
1,467 |
1.0 | ||||||||
|
Liquid Crystals2 |
383 |
443 |
589 |
741 |
895 |
916 |
878 |
733 |
– |
– |
– | ||||||||
|
Performance & Life Science Chemicals2 |
1,216 |
1,083 |
1,107 |
1,165 |
1,218 |
1,236 |
1,249 |
1,202 |
– |
– |
– | ||||||||
|
Electronic Chemicals1 |
192 |
181 |
– |
– |
– |
– |
– |
– |
– |
– |
– | ||||||||
|
Laboratory Distribution1 |
2,711 |
2,427 |
582 |
– |
– |
– |
– |
– |
– |
– |
– | ||||||||
|
Intragroup sales, Laboratory |
–246 |
–228 |
–62 |
– |
– |
– |
– |
– |
– |
– |
– | ||||||||
|
Corporate and Other |
– |
– |
200 |
76 |
34 |
29 |
7 |
– |
– |
– |
– | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
Operating result by business sector |
616 |
736 |
776 |
883 |
1,105 |
976 |
1,131 |
649 |
1,113 |
985 |
–12 | ||||||||
|
Pharmaceuticals |
272 |
389 |
391 |
454 |
524 |
417 |
655 |
403 |
579 |
350 |
–40 | ||||||||
|
Chemicals |
260 |
316 |
420 |
492 |
641 |
631 |
558 |
324 |
624 |
751 |
20 | ||||||||
|
Laboratory Distribution1 |
84 |
79 |
21 |
– |
– |
– |
– |
– |
– |
– |
– | ||||||||
|
Corporate and Other |
– |
–48 |
–56 |
–63 |
–60 |
–72 |
–81 |
–78 |
–90 |
–116 |
30 | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
Earnings before income and taxes (EBIT) |
559 |
538 |
1,044 |
956 |
1,325 |
200 |
731 |
621 |
1,113 |
1,137 |
2.2 | ||||||||
|
EBIT before depreciation and amortization (EBITDA) |
985 |
1,008 |
1,419 |
1,245 |
1,628 |
1,858 |
1,947 |
1,625 |
2,457 |
2,736 |
11 | ||||||||
|
Profit before tax |
412 |
423 |
961 |
893 |
1,273 |
–111 |
575 |
486 |
861 |
851 |
–1.2 | ||||||||
|
Profit after tax |
215 |
218 |
672 |
673 |
1,001 |
3,5203 |
379 |
377 |
642 |
629 |
–2.0 | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
Free cash flow |
441 |
442 |
1,889 |
657 |
–1,073 |
–1,4733 |
438 |
812 |
–3,522 |
1,436 |
– | ||||||||
|
Capital expenditure on property, plant and equipment |
377 |
281 |
234 |
268 |
253 |
2833 |
395 |
467 |
396 |
372 |
–6.1 | ||||||||
|
Research and development |
608 |
605 |
599 |
713 |
752 |
1,028 |
1,234 |
1,345 |
1,397 |
1,517 |
8.6 | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
Total assets |
7,511 |
6,982 |
5,754 |
7,281 |
8,102 |
14,922 |
15,645 |
16,713 |
22,388 |
22,120 |
–1.2 | ||||||||
|
Net equity |
2,054 |
2,363 |
2,800 |
3,329 |
3,807 |
8,688 |
9,563 |
9,514 |
10,372 |
10,493 |
1.2 | ||||||||
|
Employees (number as of December 31) |
34,504 |
34,206 |
28,877 |
29,133 |
29,999 |
30,968 |
32,800 |
33,062 |
40,562 |
40,676 |
0.3 | ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
Return on sales in % (ROS: Operating result / total revenues) |
8.2 |
10.0 |
12.9 |
15.0 |
17.5 |
13.8 |
14.9 |
8.4 |
12.0 |
9.6 |
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
Earnings per share in € |
1.18 |
1.15 |
3.47 |
3.40 |
5.07 |
16.213 |
1.69 |
1.68 |
2.91 |
2.84 |
–2.4 | ||||||||
|
Dividend per share in € |
1.00 |
0.80 |
0.80 |
0.85 |
0.90 |
1.20 |
1.50 |
1.00 |
1.25 |
1.50 |
20 | ||||||||
|
One-time bonus per share in € |
– |
– |
0.20 |
– |
0.15 |
2.00 |
– |
– |
– |
– |
– | ||||||||
